治疗前18F-FDG PET摄取对鼻咽癌的预后价值
回顾性分析52例鼻咽癌患者放疗(伴或不伴化疗)前18F-FDG PET/CT的SUVmax,原发灶SUVmax最佳截止值为13、淋巴结为9;原发灶SUVmax≥13和淋巴结SUVmax≥9与远处转移风险升高及无病生存期降低相关,总生存未受影响。
要点
- 原发灶SUVmax最佳截止值13,淋巴结SUVmax最佳截止值9。
- 原发灶SUVmax≥13与无病生存期降低相关(log rank χ²=2.54,p=0.017)。
- 淋巴结SUVmax≥9与远处转移风险升高(p=0.038)及无病生存期降低(log rank χ²=5.81,p=0.013)相关。
核心结论
- 治疗前18F-FDG PET/CT测定的SUVmax可能是评估鼻咽癌患者预后的有价值工具。
研究设计与样本
- 回顾性研究,纳入52例接受放疗伴或不伴化疗前18F-FDG PET/CT检查的鼻咽癌患者;27例(52%)接受三维适形放疗,25例(48%)接受调强放疗;14例(27%)接受新辅助化疗,44例(84.6%)接受同步及辅助化疗;中位随访34个月(范围5.6-66.4个月)。
诊断标准与关键数值
- 原发灶SUVmax(SUVmax-PT)最佳截止值为13,淋巴结SUVmax(SUVmax-LN)最佳截止值为9;SUVmax-PT≥13.0与远处转移风险升高相关(p=0.044),SUVmax-LN≥9与远处转移风险升高相关(p=0.038);SUVmax-PT≥13者无病生存期受影响(log rank χ²=2.54,p=0.017),SUVmax-LN≥9者无病生存期显著降低(log rank χ²=5.81,p=0.013);总生存未受SUV水平影响。
临床应用与阅片要点
- 作者认为治疗前18F-FDG PET/CT的SUVmax可能是评估鼻咽癌预后的有价值工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the prognostic value of maximal standardized uptake values (SUVmax) from serial fluor-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS: Fifty-two patients with NPC who underwent 18F-FDG PET/CT scan before radiotherapy with/without chemotherapy were reviewed retrospectively. Twenty-seven patients (52%) were applied 3-D conformal radiotherapy and 25 patients (48%) applied intensity-modulated radiotherapy (IMRT). Fourteen (27%) patients were given neoadjuvant chemotherapy and forty-four (84.6%) patients were given concomitant and adjuvant chemotherapy.
RESULTS: Median follow-up time was 34 months (range 5.6-66.4 months). Forty-four (84.6%) patients were alive at last follow-up and eight (15.4%) had died. The best cut-off value of the SUVmax for the primary tumor site (SUVmax-PT) was 13 and 9 for the lymph nodes (SUVmax-LN). Patients with SUVmax-PT ≥ 13.0 and SUVmax-LN ≥ 9 had a significantly higher risk for the development of the distant metastases (p = 0.044 and p = 0.038). DFS was affected in patients with SUVmax-PT ≥ 13 (log rank χ 2 = 2.54, p = 0.017) and was significantly lower in patients with SUVmax-LN ≥ 9 for the lymph nodes (log rank χ 2 = 5.81, p = 0.013). OS was not affected by SUV levels. A multivariate Cox proportional hazard model of DFS included age (≥ 40), SUVmax-LN (< 9), T stage (T1-2) and neoadjuvant chemotherapy are significantly better prognosis for the DFS.
CONCLUSION: 18F-FDG PET/CT uptake before treatment, as determined by SUVmax, may be a valuable tool to evaluate prognosis in NPC patients.
引用
- Aktan M, Kanyilmaz G, Yavuz BB, et al. Prognostic value of pre-treatment 18F-FDG PET uptake for nasopharyngeal carcinoma. Radiol Med. 2017. PMID: 29177728. doi:10.1007/s11547-017-0837-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。